| Year |
Citation |
Score |
| 2015 |
Majer P, Mohr PN, Heekeren HR, Härdle WK. Portfolio Decisions and Brain Reactions via the CEAD method. Psychometrika. PMID 25670029 DOI: 10.1007/S11336-015-9441-5 |
0.602 |
|
| 2014 |
van Bömmel A, Song S, Majer P, Mohr PN, Heekeren HR, Härdle WK. Risk patterns and correlated brain activities. Multidimensional statistical analysis of FMRI data in economic decision making study. Psychometrika. 79: 489-514. PMID 25205006 DOI: 10.1007/S11336-013-9352-2 |
0.618 |
|
| 2014 |
Schulreich S, Heussen YG, Gerhardt H, Mohr PN, Binkofski FC, Koelsch S, Heekeren HR. Music-evoked incidental happiness modulates probability weighting during risky lottery choices. Frontiers in Psychology. 4: 981. PMID 24432007 DOI: 10.3389/Fpsyg.2013.00981 |
0.594 |
|
| 2014 |
Riedl R, Mohr P, Kenning P, Davis F, Heekeren H. Trusting humans and avatars: A brain imaging study based on evolution theory Journal of Management Information Systems. 30: 83-114. DOI: 10.2753/Mis0742-1222300404 |
0.498 |
|
| 2013 |
Preuschoff K, Mohr PN, Hsu M. Decision making under uncertainty. Frontiers in Neuroscience. 7: 218. PMID 24311997 DOI: 10.3389/Fnins.2013.00218 |
0.452 |
|
| 2012 |
Bruehl H, Mohr PN, Hatri A, Heekeren HR. Acute stress prompts riskier decisions in young men European Journal of Psychotraumatology. 3. DOI: 10.3402/Ejpt.V3I0.19322 |
0.524 |
|
| 2010 |
Mohr PN, Nagel IE. Variability in brain activity as an individual difference measure in neuroscience? The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 7755-7. PMID 20534823 DOI: 10.1523/Jneurosci.1560-10.2010 |
0.311 |
|
| 2010 |
Mohr PN, Biele G, Heekeren HR. Neural processing of risk. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 6613-9. PMID 20463224 DOI: 10.1523/Jneurosci.0003-10.2010 |
0.605 |
|
| 2010 |
Mohr PN, Biele G, Krugel LK, Li SC, Heekeren HR. Neural foundations of risk-return trade-off in investment decisions. Neuroimage. 49: 2556-63. PMID 19879367 DOI: 10.1016/J.Neuroimage.2009.10.060 |
0.618 |
|
| 2010 |
Mohr PN, Li SC, Heekeren HR. Neuroeconomics and aging: neuromodulation of economic decision making in old age. Neuroscience and Biobehavioral Reviews. 34: 678-88. PMID 19501615 DOI: 10.1016/J.Neubiorev.2009.05.010 |
0.568 |
|
| 2009 |
Krugel LK, Biele G, Mohr PN, Li SC, Heekeren HR. Genetic variation in dopaminergic neuromodulation influences the ability to rapidly and flexibly adapt decisions. Proceedings of the National Academy of Sciences of the United States of America. 106: 17951-6. PMID 19822738 DOI: 10.1073/Pnas.0905191106 |
0.556 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2009 |
de Vicente J, Hendricks RT, Smith DB, Fell JB, Fischer J, Spencer SR, Stengel PJ, Mohr P, Robinson JE, Blake JF, Hilgenkamp RK, Yee C, Adjabeng G, Elworthy TR, Li J, et al. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides. Bioorganic & Medicinal Chemistry Letters. 19: 5652-6. PMID 19709881 DOI: 10.1016/J.Bmcl.2009.08.022 |
0.211 |
|
| 2021 |
Lodde G, Forschner A, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Schilling B, Loquai C, Berking C, Hüning S, Schatton K, Gebhardt C, Eckardt J, Gutzmer R, et al. Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. Cancers. 13. PMID 34065995 DOI: 10.3390/cancers13102319 |
0.206 |
|
| 2014 |
Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, et al. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2. Bioorganic & Medicinal Chemistry Letters. 24: 2635-9. PMID 24813737 DOI: 10.1016/J.Bmcl.2014.04.068 |
0.2 |
|
| 2009 |
de Vicente J, Hendricks RT, Smith DB, Fell JB, Fischer J, Spencer SR, Stengel PJ, Mohr P, Robinson JE, Blake JF, Hilgenkamp RK, Yee C, Adjabeng G, Elworthy TR, Tracy J, et al. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones. Bioorganic & Medicinal Chemistry Letters. 19: 3642-6. PMID 19457662 DOI: 10.1016/J.Bmcl.2009.05.004 |
0.193 |
|
| 2009 |
de Vicente J, Hendricks RT, Smith DB, Fell JB, Fischer J, Spencer SR, Stengel PJ, Mohr P, Robinson JE, Blake JF, Hilgenkamp RK, Yee C, Zhao J, Elworthy TR, Tracy J, et al. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids. Bioorganic & Medicinal Chemistry Letters. 19: 5648-51. PMID 19700319 DOI: 10.1016/J.Bmcl.2009.08.023 |
0.189 |
|
| 2020 |
Glutsch V, Amaral T, Garbe C, Thoms KM, Mohr P, Hauschild A, Schilling B. Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase. Acta Dermato-Venereologica. 100: adv00174. PMID 32449784 DOI: 10.2340/00015555-3526 |
0.181 |
|
| 2019 |
Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, et al. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncology (London, England). PMID 31870188 DOI: 10.2217/fon-2019-0666 |
0.138 |
|
| 2013 |
Ascierto PA, Gogas HJ, Grob JJ, Algarra SM, Mohr P, Hansson J, Hauschild A. Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review Critical Reviews in Oncology/Hematology. 85: 149-161. PMID 22874771 DOI: 10.1016/j.critrevonc.2012.07.004 |
0.137 |
|
| 2019 |
Krensel M, Petersen J, Mohr P, Weishaupt C, Augustin J, Schäfer I. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 17: 1239-1250. PMID 31885173 DOI: 10.1111/ddg.14002_g |
0.12 |
|
| 2024 |
Kirkwood JM, Vecchio MD, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, et al. Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery. Future Oncology (London, England). PMID 38390818 DOI: 10.2217/fon-2023-0977 |
0.12 |
|
| 2009 |
Mohr P, Hauschild A, Trefzer U, Weichenthal M. Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e70; author reply e7. PMID 19620476 DOI: 10.1200/JCO.2009.23.3874 |
0.107 |
|
| 2018 |
Mahmoodi J, Čurdová J, Henking C, Kunz M, Matić K, Mohr P, Vovko M. Internet Users' Valuation of Enhanced Data Protection on Social Media: Which Aspects of Privacy Are Worth the Most? Frontiers in Psychology. 9: 1516. PMID 30186203 DOI: 10.3389/fpsyg.2018.01516 |
0.1 |
|
| 2023 |
Leiter U, Heppt MV, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, ElGammal AKS, Felcht M, ... ... Mohr P, et al. S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. PMID 37840404 DOI: 10.1111/ddg.15256 |
0.097 |
|
| 2023 |
Franklin C, Mohr P, Bluhm L, Meier F, Garzarolli M, Weichenthal M, Kähler K, Grimmelmann I, Gutzmer R, Utikal J, Terheyden P, Herbst R, Haferkamp S, Pfoehler C, Forschner A, et al. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. Journal For Immunotherapy of Cancer. 11. PMID 37028819 DOI: 10.1136/jitc-2022-005828 |
0.095 |
|
| 2010 |
Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 841-6. PMID 20048184 DOI: 10.1200/JCO.2009.23.1704 |
0.094 |
|
| 2011 |
Hofmann MA, Hauschild A, Mohr P, Garbe C, Weichenthal M, Trefzer U, Drecoll U, Tilgen W, Schadendorf D, Kaatz M, Ulrich J. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial. Melanoma Research. 21: 516-23. PMID 22076216 DOI: 10.1097/CMR.0b013e3283485ff0 |
0.093 |
|
| 2023 |
Berking C, Livingstone E, Debus D, Loquai C, Weichenthal M, Leiter U, Kiecker F, Mohr P, Eigentler TK, Remy J, Schober K, Heppt MV, von Wasielewski I, Schadendorf D, Gutzmer R. COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma. Cancers. 15. PMID 37760406 DOI: 10.3390/cancers15184436 |
0.093 |
|
| 2023 |
Kuhn B, Peters JU, Rudolph MG, Mohr P, Stahl M, Tosstorff A. Details Matter in Structure-based Drug Design. Chimia. 77: 489-493. PMID 38047790 DOI: 10.2533/chimia.2023.489 |
0.093 |
|
| 2012 |
Dietz M, Mohr P, Kuhn B, Maerki HP, Hartman P, Ruf A, Benz J, Grether U, Wright MB. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. Chemmedchem. 7: 1101-11. PMID 22489042 DOI: 10.1002/cmdc.201100598 |
0.09 |
|
| 2009 |
Pierson PD, Fettes A, Freichel C, Gatti-McArthur S, Hertel C, Huwyler J, Mohr P, Nakagawa T, Nettekoven M, Plancher JM, Raab S, Richter H, Roche O, Rodríguez Sarmiento RM, Schmitt M, et al. 5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity. Journal of Medicinal Chemistry. 52: 3855-68. PMID 19456097 DOI: 10.1021/jm900409x |
0.088 |
|
| 2021 |
Eggermont AM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV, Barrow C, Di Giacomo AM, Fisher R, Sandhu S, Kudchadkar R, Ortiz Romero PL, Svane IM, Larkin J, Puig S, ... ... Mohr P, et al. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer (Oxford, England : 1990). 158: 156-168. PMID 34678677 DOI: 10.1016/j.ejca.2021.09.023 |
0.085 |
|
| 2013 |
Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, ... ... Mohr P, et al. Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 11: 1-116, 1-126. PMID 24028775 DOI: 10.1111/Ddg.12113_Suppl |
0.083 |
|
| 2022 |
Franklin C, Mohr P, Bluhm L, Grimmelmann I, Gutzmer R, Meier F, Garzarolli M, Weichenthal M, Pfoehler C, Herbst R, Terheyden P, Utikal J, Ulrich J, Debus D, Haferkamp S, et al. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. Journal For Immunotherapy of Cancer. 10. PMID 35688555 DOI: 10.1136/jitc-2022-004509 |
0.083 |
|
| 2023 |
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, et al. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature Medicine. PMID 37845511 DOI: 10.1038/s41591-023-02583-2 |
0.082 |
|
| 2023 |
Edelmann MR, Bredack C, Belli S, Mohr P, Imhoff MP, Reggiani F, Kusznir EA, Rufer AC, Holt DP, Valentine H, Wong DF, Dannals RF, Honer M, Gobbi LC. Evaluation of Tetrazine Tracers for Pretargeted Imaging within the Central Nervous System. Bioconjugate Chemistry. PMID 37710950 DOI: 10.1021/acs.bioconjchem.3c00385 |
0.081 |
|
| 2022 |
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, ... ... Mohr P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet (London, England). PMID 35367007 DOI: 10.1016/S0140-6736(22)00562-1 |
0.078 |
|
| 2014 |
Hamid O, Ilaria R, Garbe C, Wolter P, Maio M, Hutson TE, Arance A, Lorigan P, Lee J, Hauschild A, Mohr P, Hahka-Kemppinen M, Kaiser C, Turner PK, Conti I, et al. A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. Cancer. 120: 2016-24. PMID 24676877 DOI: 10.1002/cncr.28635 |
0.077 |
|
| 2023 |
Skreinig LR, Kalkofen D, Stanescu A, Mohr P, Heyen F, Mori S, Sedlmair M, Schmalstieg D, Plopski A. guitARhero: Interactive Augmented Reality Guitar Tutorials. Ieee Transactions On Visualization and Computer Graphics. 29: 4676-4685. PMID 37773918 DOI: 10.1109/TVCG.2023.3320266 |
0.077 |
|
| 2022 |
Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, ... Mohr P, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. The Lancet. Oncology. PMID 36265502 DOI: 10.1016/S1470-2045(22)00559-9 |
0.076 |
|
| 2022 |
Khattak MA, Luke JJ, Long GV, Ascierto PA, Rutkowski P, Schadendorf D, Robert C, Grob JJ, de la Cruz Merino L, Del Vecchio M, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Carlino MS, Mohr P, et al. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. European Journal of Cancer (Oxford, England : 1990). PMID 36202690 DOI: 10.1016/j.ejca.2022.08.004 |
0.075 |
|
| 2023 |
Lodde GC, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Hauschild A, Schilling B, Loquai C, Berking C, Hüning S, Eckardt J, Gutzmer R, Reinhardt L, Glutsch V, et al. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study. European Journal of Cancer (Oxford, England : 1990). 191: 112957. PMID 37487400 DOI: 10.1016/j.ejca.2023.112957 |
0.075 |
|
| 2009 |
Hauschild A, Weichenthal M, Rass K, Linse R, Ulrich J, Stadler R, Volkenandt M, Grabbe S, Proske U, Schadendorf D, Brockmeyer N, Vogt T, Rompel R, Kaufmann R, Kaatz M, ... ... Mohr P, et al. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3496-502. PMID 19433681 DOI: 10.1200/JCO.2008.21.3892 |
0.074 |
|
| 2016 |
Wilden SM, Lang BM, Mohr P, Grabbe S. Immune checkpoint inhibitors: a milestone in the treatment of melanoma. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 14: 685-95. PMID 27373242 DOI: 10.1111/ddg.13012 |
0.073 |
|
| 2019 |
Ugurel S, Kortmann RD, Mohr P, Mentzel T, Garbe C, Breuninger H, Bauer S, Grabbe S. S1 guidelines for dermatofibrosarcoma protuberans (DFSP) - update 2018. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. PMID 31115967 DOI: 10.1111/ddg.13849 |
0.072 |
|
| 2006 |
Kuhn B, Hilpert H, Benz J, Binggeli A, Grether U, Humm R, Märki HP, Meyer M, Mohr P. Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists. Bioorganic & Medicinal Chemistry Letters. 16: 4016-20. PMID 16737814 DOI: 10.1016/j.bmcl.2006.05.007 |
0.072 |
|
| 2010 |
Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, Bostroem A, Heese O, Koelbl O, Garbe C, Schadendorf D. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 117: 1697-703. PMID 21472716 DOI: 10.1002/cncr.25631 |
0.072 |
|
| 2020 |
Knispel S, Stang A, Zimmer L, Lax H, Gutzmer R, Heinzerling L, Weishaupt C, Pföhler C, Gesierich A, Herbst R, Kaehler KC, Weide B, Berking C, Loquai C, Utikal J, ... ... Mohr P, et al. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. Journal For Immunotherapy of Cancer. 8. PMID 32371460 DOI: 10.1136/jitc-2019-000395 |
0.072 |
|
| 2019 |
Gorges K, Wiltfang L, Gorges TM, Sartori A, Hildebrandt L, Keller L, Volkmer B, Peine S, Babayan A, Moll I, Schneider SW, Twarock S, Mohr P, Fischer JW, Pantel K. Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. Cancers. 11. PMID 31671846 DOI: 10.3390/cancers11111685 |
0.072 |
|
| 2023 |
Kähler KC, Debus D, Schley G, Göppner D, Hassel JC, Meier F, Terheyden P, Stadler R, Tüting T, Kaatz M, Hoff NP, Masoudi E, Zdanowicz-Specht A, Nguyen MT, Mohr P. Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS. Melanoma Research. PMID 37962220 DOI: 10.1097/CMR.0000000000000908 |
0.069 |
|
| 2022 |
Koch EAT, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R, Hassel JC, Haferkamp S, Kähler KC, Knorr H, Kreuzberg N, Leiter U, Loquai C, Meier F, Meissner M, ... Mohr P, et al. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. Cancers. 14. PMID 35158786 DOI: 10.3390/cancers14030518 |
0.069 |
|
| 2015 |
Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, ... ... Mohr P, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet. Oncology. 16: 375-84. PMID 25795410 DOI: 10.1016/S1470-2045(15)70076-8 |
0.069 |
|
| 2023 |
Lodde GC, Jansen P, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Sucker A, Placke JM, et al. Characterisation and outcome of RAC1 mutated melanoma. European Journal of Cancer (Oxford, England : 1990). 183: 1-10. PMID 36773463 DOI: 10.1016/j.ejca.2023.01.009 |
0.068 |
|
| 2015 |
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, ... Mohr P, et al. Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science (New York, N.Y.). PMID 26359337 DOI: 10.1126/Science.Aad0095 |
0.067 |
|
| 2021 |
Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, Hassel JC, Weishaupt C, Eigentler T, Schilling B, Schummer P, Sirokay J, Kiecker F, Owen CN, ... ... Mohr P, et al. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer (Oxford, England : 1990). 148: 61-75. PMID 33735811 DOI: 10.1016/j.ejca.2021.01.034 |
0.067 |
|
| 2023 |
Ebner C, Mohr P, Langlotz T, Peng Y, Schmalstieg D, Wetzstein G, Kalkofen D. Off-Axis Layered Displays: Hybrid Direct-View/Near-Eye Mixed Reality with Focus Cues. Ieee Transactions On Visualization and Computer Graphics. PMID 37027729 DOI: 10.1109/TVCG.2023.3247077 |
0.067 |
|
| 2014 |
Trefzer U, Gutzmer R, Wilhelm T, Schenck F, Kähler KC, Jacobi V, Witthohn K, Lentzen H, Mohr P. Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study. Journal For Immunotherapy of Cancer. 2: 27. PMID 25324973 DOI: 10.1186/s40425-014-0027-z |
0.066 |
|
| 2022 |
Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kiecker F, Dippel E, et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet (London, England). 400: 1117-1129. PMID 36099927 DOI: 10.1016/S0140-6736(22)01654-3 |
0.066 |
|
| 2015 |
Zimmer L, Eigentler TK, Kiecker F, Simon J, Utikal J, Mohr P, Berking C, Kämpgen E, Dippel E, Stadler R, Hauschild A, Fluck M, Terheyden P, Rompel R, Loquai C, et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. Journal of Translational Medicine. 13: 351. PMID 26541511 DOI: 10.1186/s12967-015-0716-5 |
0.066 |
|
| 2011 |
Diez C, Mohr P, Girndt M, Puehler T, Haneya A, Silber RE, Hofmann HS. Impact of estimated glomerular filtration rate after valve and combined valve and coronary surgery. Asaio Journal (American Society For Artificial Internal Organs : 1992). 56: 543-9. PMID 20944500 DOI: 10.1097/MAT.0b013e3181f7475f |
0.066 |
|
| 2023 |
Bossi P, Ascierto PA, Basset-Seguin N, Dreno B, Dummer R, Hauschild A, Mohr P, Kaufmann R, Pellacani G, Puig S, Moreno-Ramírez D, Robert C, Stratigos A, Gutzmer R, Queirolo P, et al. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. Critical Reviews in Oncology/Hematology. 104066. PMID 37442495 DOI: 10.1016/j.critrevonc.2023.104066 |
0.066 |
|
| 2022 |
Haist M, Stege H, Lang BM, Tsochataridou A, Salzmann M, Mohr P, Schadendorf D, Ugurel S, Placke JM, Weichenthal M, Gutzmer R, Leiter U, Kaatz M, Haferkamp S, Berking C, et al. Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry. Cancers. 14. PMID 36428636 DOI: 10.3390/cancers14225543 |
0.064 |
|
| 2022 |
Stanescu A, Mohr P, Schmalstieg D, Kalkofen D. Model-Free Authoring By Demonstration of Assembly Instructions in Augmented Reality. Ieee Transactions On Visualization and Computer Graphics. PMID 36048990 DOI: 10.1109/TVCG.2022.3203104 |
0.064 |
|
| 2009 |
Grether U, Bénardeau A, Benz J, Binggeli A, Blum D, Hilpert H, Kuhn B, Märki HP, Meyer M, Mohr P, Püntener K, Raab S, Ruf A, Schlatter D. Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists. Chemmedchem. 4: 951-6. PMID 19326383 DOI: 10.1002/cmdc.200800425 |
0.064 |
|
| 2022 |
Kaatz M, Mohr P, Livingstone E, Weichenthal M, Kreuter A, Pföhler C, Leiter U, Ulrich J, Utikal JS, Gutzmer R, Herbst R, Schadendorf D. Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS. Acta Dermato-Venereologica. PMID 35199180 DOI: 10.2340/actadv.v102.293 |
0.063 |
|
| 2003 |
Neuber K, Reinhold U, Deutschmann A, Pföhler C, Mohr P, Pichlmeier U, Baumgart J, Hauschild A. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. Melanoma Research. 13: 81-5. PMID 12569289 DOI: 10.1097/00008390-200302000-00013 |
0.063 |
|
| 2020 |
Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kieker F, Dippel E, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England). 395: 1558-1568. PMID 32416781 DOI: 10.1016/S0140-6736(20)30417-7 |
0.062 |
|
| 2021 |
Koch EAT, Petzold A, Wessely A, Dippel E, Erdmann M, Heinzerling L, Hohberger B, Knorr H, Leiter U, Meier F, Mohr P, Rahimi F, Schell B, Schlaak M, Terheyden P, et al. Clinical determinants of long-term survival in metastatic uveal melanoma. Cancer Immunology, Immunotherapy : Cii. PMID 34709438 DOI: 10.1007/s00262-021-03090-4 |
0.062 |
|
| 2022 |
Kreft S, Glutsch V, Zaremba A, Schummer P, Mohr P, Grimmelmann I, Gutzmer R, Meier F, Pföhler C, Sachse MM, Meiss F, Forschner A, Haferkamp S, Welzel J, Terheyden P, et al. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG. European Journal of Cancer (Oxford, England : 1990). 167: 32-41. PMID 35366571 DOI: 10.1016/j.ejca.2022.02.023 |
0.061 |
|
| 2023 |
Koch EAT, Petzold A, Wessely A, Dippel E, Eckstein M, Gesierich A, Gutzmer R, Hassel JC, Knorr H, Kreuzberg N, Leiter U, Loquai C, Meier F, Meissner M, Mohr P, et al. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial. Frontiers of Medicine. PMID 37432641 DOI: 10.1007/s11684-023-0993-y |
0.061 |
|
| 2015 |
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, ... ... Mohr P, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (London, England). 386: 444-51. PMID 26037941 DOI: 10.1016/S0140-6736(15)60898-4 |
0.061 |
|
| 2013 |
Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, ... ... Mohr P, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. Plos One. 8: e53745. PMID 23341990 DOI: 10.1371/journal.pone.0053745 |
0.06 |
|
| 2017 |
Cosgarea I, Ugurel S, Sucker A, Livingstone E, Zimmer L, Ziemer M, Utikal J, Mohr P, Pfeiffer C, Pföhler C, Hillen U, Horn S, Schadendorf D, Griewank KG, Roesch A. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations. Oncotarget. PMID 28380455 DOI: 10.18632/oncotarget.16542 |
0.06 |
|
| 2009 |
Diez C, Mohr P, Koch D, Silber RE, Schmid C, Hofmann HS. Age- and gender-specific values of estimated glomerular filtration rate among 6232 patients undergoing cardiac surgery. Interactive Cardiovascular and Thoracic Surgery. 9: 593-7. PMID 19584070 DOI: 10.1510/icvts.2009.208033 |
0.058 |
|
| 2023 |
Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler TK, Hauschild A, Kiecker F, Hassel JC, Mohr P, Fluck M, Thomas I, et al. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. Lancet (London, England). PMID 37451295 DOI: 10.1016/S0140-6736(23)00769-9 |
0.058 |
|
| 2019 |
Cowley JA, Rao M, Mohr P, Moody NJ, Sellars MJ, Crane MS. TaqMan real-time and conventional nested PCR tests specific to Yellow head virus genotype 7 (YHV7) identified in Giant tiger shrimp in Australia. Journal of Virological Methods. 113689. PMID 31276700 DOI: 10.1016/j.jviromet.2019.113689 |
0.058 |
|
| 2012 |
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. The New England Journal of Medicine. 367: 107-14. PMID 22663011 DOI: 10.1056/NEJMoa1203421 |
0.058 |
|
| 2022 |
Mohr P, Scherrer E, Assaf C, Bender M, Berking C, Chandwani S, Eigentler T, Grimmelmann I, Gutzmer R, Haferkamp S, Hassel JC, Hauschild A, Herbst R, Jiang R, Kähler KC, et al. Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers. 14. PMID 35406577 DOI: 10.3390/cancers14071804 |
0.058 |
|
| 2018 |
Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, Terheyden P, Krause-Bergmann A, Schulze HJ, Hassel J, Lahner N, Wollina U, Ziller F, Utikal J, Hafner C, ... ... Mohr P, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. European Journal of Cancer (Oxford, England : 1990). 96: 34-43. PMID 29665511 DOI: 10.1016/j.ejca.2018.01.075 |
0.058 |
|
| 2015 |
Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kämpgen E, Livingstone E, Bluhm L, Rompel R, Griewank KG, Fluck M, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. Plos One. 10: e0118564. PMID 25761109 DOI: 10.1371/journal.pone.0118564 |
0.058 |
|
| 2009 |
Bénardeau A, Benz J, Binggeli A, Blum D, Boehringer M, Grether U, Hilpert H, Kuhn B, Märki HP, Meyer M, Püntener K, Raab S, Ruf A, Schlatter D, Mohr P. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. Bioorganic & Medicinal Chemistry Letters. 19: 2468-73. PMID 19349176 DOI: 10.1016/j.bmcl.2009.03.036 |
0.057 |
|
| 2023 |
Hassel JC, Zimmer L, Sickmann T, Eigentler TK, Meier F, Mohr P, Pukrop T, Roesch A, Vordermark D, Wendl C, Gutzmer R. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers. 15. PMID 37444558 DOI: 10.3390/cancers15133448 |
0.057 |
|
| 2021 |
Stege H, Haist M, Schultheis M, Fleischer MI, Mohr P, Meier F, Schadendorf D, Ugurel S, Livingstone E, Zimmer L, Herbst R, Pföhler C, Kähler K, Weichenthal M, Terheyden P, et al. Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study. Cancers. 13. PMID 34065877 DOI: 10.3390/cancers13102312 |
0.056 |
|
| 2022 |
Spassova I, Ugurel S, Kubat L, Zimmer L, Terheyden P, Mohr A, Björn Andtback H, Villabona L, Leiter U, Eigentler T, Loquai C, Hassel JC, Gambichler T, Haferkamp S, Mohr P, et al. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma. Journal For Immunotherapy of Cancer. 10. PMID 35074902 DOI: 10.1136/jitc-2021-003198 |
0.055 |
|
| 2017 |
Becker JC, Lorenz E, Ugurel S, Eigentler TK, Kiecker F, Pföhler C, Kellner I, Meier F, Kähler K, Mohr P, Berking C, Haas G, Helwig C, Oksen D, Schadendorf D, et al. Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget. 8: 79731-79741. PMID 29108353 DOI: 10.18632/oncotarget.19218 |
0.055 |
|
| 2017 |
Harries M, Mohr P, Grange F, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod L, Wolowacz S, A Kaye J, Kontoudis I. Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: A retrospective and prospective observational study (MELABIS). International Journal of Clinical Practice. 71. PMID 28508460 DOI: 10.1111/ijcp.12946 |
0.054 |
|
| 2010 |
Kitas E, Mohr P, Kuhn B, Hebeisen P, Wessel HP, Haap W, Ruf A, Benz J, Joseph C, Huber W, Sanchez RA, Paehler A, Benardeau A, Gubler M, Schott B, et al. Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes. Bioorganic & Medicinal Chemistry Letters. 20: 594-9. PMID 19969452 DOI: 10.1016/j.bmcl.2009.11.093 |
0.054 |
|
| 2016 |
Huebner J, Mohr P, Simon JC, Fluck M, Berking C, Zimmer L, Loquai C. Use of complementary medicine in metastatic melanoma patients treated with ipilimumab within a clinical trial. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 14: 508-13. PMID 27119474 DOI: 10.1111/ddg.12750 |
0.053 |
|
| 2019 |
Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, et al. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. Melanoma Management. 6: MMT33. PMID 31871622 DOI: 10.2217/mmt-2019-0015 |
0.053 |
|
| 2011 |
Hebeisen P, Haap W, Kuhn B, Mohr P, Wessel HP, Zutter U, Kirchner S, Ruf A, Benz J, Joseph C, Alvarez-Sánchez R, Gubler M, Schott B, Benardeau A, Tozzo E, et al. Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase. Bioorganic & Medicinal Chemistry Letters. 21: 3237-42. PMID 21550236 DOI: 10.1016/j.bmcl.2011.04.044 |
0.053 |
|
| 2015 |
Schneider SM, Malecki AK, Müller K, Schönfeld R, Girndt M, Mohr P, Hiss M, Kielstein H, Jäger K, Kielstein JT. Effect of a single dialysis session on cognitive function in CKD5D patients: a prospective clinical study. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 30: 1551-9. PMID 26071228 DOI: 10.1093/ndt/gfv213 |
0.052 |
|
| 2015 |
Mohr P, Hauschild A, Trefzer U, Enk A, Tilgen W, Loquai C, Gogas H, Haalck T, Koller J, Dummer R, Gutzmer R, Brockmeyer N, Hölzle E, Sunderkötter C, Mauch C, et al. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26503196 DOI: 10.1200/JCO.2014.59.6932 |
0.052 |
|
| 2021 |
Leiter-Stöppke U, Mohr P, Gutzmer R. Update - Systemtherapie beim Basalzellkarzinom. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 19: 1399-1400. PMID 34541806 DOI: 10.1111/ddg.14599_g |
0.052 |
|
| 2014 |
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, ... ... Mohr P, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. The New England Journal of Medicine. 371: 1877-88. PMID 25265492 DOI: 10.1056/NEJMoa1406037 |
0.051 |
|
| 2013 |
Mohr P, Birgersson U, Berking C, Henderson C, Trefzer U, Kemeny L, Sunderkötter C, Dirschka T, Motley R, Frohm-Nilsson M, Reinhold U, Loquai C, Braun R, Nyberg F, Paoli J. Electrical impedance spectroscopy as a potential adjunct diagnostic tool for cutaneous melanoma. Skin Research and Technology : Official Journal of International Society For Bioengineering and the Skin (Isbs) [and] International Society For Digital Imaging of Skin (Isdis) [and] International Society For Skin Imaging (Issi). 19: 75-83. PMID 23350668 DOI: 10.1111/srt.12008 |
0.049 |
|
| 2022 |
Pires da Silva I, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T, Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, Pföhler C, ... ... Mohr P, et al. Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101701. PMID 35143285 DOI: 10.1200/JCO.21.01701 |
0.048 |
|
| 2020 |
Leiter U, Loquai C, Reinhardt L, Rafei-Shamsabadi D, Gutzmer R, Kaehler K, Heinzerling L, Hassel JC, Glutsch V, Sirokay J, Schlecht N, Rübben A, Gambichler T, Schatton K, Pfoehler C, ... ... Mohr P, et al. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. Journal For Immunotherapy of Cancer. 8. PMID 33093156 DOI: 10.1136/jitc-2020-000897 |
0.048 |
|
| 2021 |
Thielmann CM, Chorti E, Matull J, Murali R, Zaremba A, Lodde G, Jansen P, Richter L, Kretz J, Möller I, Sucker A, Herbst R, Terheyden P, Utikal J, Pföhler C, ... ... Mohr P, et al. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. European Journal of Cancer (Oxford, England : 1990). 159: 113-124. PMID 34742158 DOI: 10.1016/j.ejca.2021.09.035 |
0.047 |
|
| 2011 |
Aberg P, Birgersson U, Elsner P, Mohr P, Ollmar S. Electrical impedance spectroscopy and the diagnostic accuracy for malignant melanoma. Experimental Dermatology. 20: 648-52. PMID 21539620 DOI: 10.1111/j.1600-0625.2011.01285.x |
0.047 |
|
| 2020 |
Samsing F, Hoad J, Mohr P, Dearnley M, Wynne JW. Comparative transcriptome analysis of pilchard orthomyxovirus (POMV) and infectious salmon anaemia virus (ISAV). Fish & Shellfish Immunology. PMID 32629102 DOI: 10.1016/j.fsi.2020.06.050 |
0.047 |
|
| 2015 |
Tolk H, Satzger I, Mohr P, Zimmer L, Weide B, Schäd S, Gutzmer R. Complete remission of metastatic melanoma upon BRAF inhibitor treatment-what happens after discontinuation? Melanoma Research. 25: 362-366. PMID 26061438 DOI: 10.1097/CMR.0000000000000169 |
0.047 |
|
| 2023 |
Placke JM, Kimmig M, Griewank K, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Welzel J, Engel DR, et al. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM. Ebiomedicine. 96: 104774. PMID 37660535 DOI: 10.1016/j.ebiom.2023.104774 |
0.047 |
|
| 2023 |
Zaremba A, Mohr P, Gutzmer R, Meier F, Pföhler C, Weichenthal M, Terheyden P, Forschner A, Leiter U, Ulrich J, Utikal J, Welzel J, Kaatz M, Gebhardt C, Herbst R, et al. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG. European Journal of Cancer (Oxford, England : 1990). 188: 140-151. PMID 37245442 DOI: 10.1016/j.ejca.2023.04.008 |
0.047 |
|
| 2019 |
Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A, et al. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. European Journal of Cancer (Oxford, England : 1990). 109: 61-69. PMID 30690294 DOI: 10.1016/j.ejca.2018.12.015 |
0.047 |
|
| 2017 |
Grange F, Mohr P, Harries M, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod LD, Kaye JA, Wolowacz S, Kontoudis I. Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study). Melanoma Research. PMID 28800027 DOI: 10.1097/CMR.0000000000000372 |
0.047 |
|
| 2024 |
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, et al. Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature Medicine. PMID 38177857 DOI: 10.1038/s41591-023-02775-w |
0.046 |
|
| 2023 |
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, et al. Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature Medicine. PMID 37923838 DOI: 10.1038/s41591-023-02661-5 |
0.046 |
|
| 2017 |
Schaper-Gerhardt K, Okoye S, Herbst R, Ulrich J, Terheyden P, Pföhler C, Utikal JS, Kreuter A, Mohr P, Dippel E, Satzger I, Sucker A, Schadendorf D, Ugurel S, Gutzmer R. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. European Journal of Cancer (Oxford, England : 1990). 88: 67-76. PMID 29195116 DOI: 10.1016/j.ejca.2017.10.026 |
0.046 |
|
| 2021 |
Placke JM, Soun C, Bottek J, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Pfeiffer C, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, et al. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. Frontiers in Oncology. 11: 741993. PMID 34621681 DOI: 10.3389/fonc.2021.741993 |
0.046 |
|
| 2020 |
Schneegans S, Lück L, Besler K, Bluhm L, Stadler JC, Staub J, Greinert R, Volkmer B, Kubista M, Gebhardt C, Sartori A, Irwin D, Serkkola E, Af Hällström T, Lianidou E, ... ... Mohr P, et al. Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. Molecular Oncology. PMID 32246814 DOI: 10.1002/1878-0261.12669 |
0.045 |
|
| 2014 |
Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pföhler C, Schiller M, Hauschild A, Hein R, Kämpgen E, Kellner I, Leverkus M, Becker JC, Ströbel P, Schadendorf D. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 499-510. PMID 24173542 DOI: 10.1158/1078-0432.CCR-13-1411 |
0.045 |
|
| 2022 |
Rossetti GG, Ossorio MA, Rempel S, Kratzel A, Dionellis VS, Barriot S, Tropia L, Gorgulla C, Arthanari H, Thiel V, Mohr P, Gamboni R, Halazonetis TD. Non-covalent SARS-CoV-2 M inhibitors developed from in silico screen hits. Scientific Reports. 12: 2505. PMID 35169179 DOI: 10.1038/s41598-022-06306-4 |
0.045 |
|
| 2021 |
Koch EAT, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R, Hassel JC, Haferkamp S, Hohberger B, Kähler KC, Knorr H, Kreuzberg N, Leiter U, Loquai C, Meier F, ... ... Mohr P, et al. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Cancers. 13. PMID 34283061 DOI: 10.3390/cancers13133359 |
0.044 |
|
| 2020 |
Louie KS, Banks V, Scholz F, Richter H, Öhrling K, Mohr P, Haferkamp S. Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database. Future Oncology (London, England). PMID 32050787 DOI: 10.2217/fon-2019-0838 |
0.043 |
|
| 2014 |
Eigentler TK, Schlaak M, Hassel JC, Loquai C, Stoffels I, Gutzmer R, Pätzold S, Mohr P, Keller U, Starz H, Ulrich J, Tsianakas A, Kähler K, Hauschild A, Janssen E, et al. Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. Journal of Immunotherapy (Hagerstown, Md. : 1997). 37: 374-81. PMID 25075567 DOI: 10.1097/CJI.0000000000000046 |
0.042 |
|
| 2012 |
Nashan D, Reuter K, Mohr P, Agarwala SS. Understanding and managing interferon-α-related fatigue in patients with melanoma. Melanoma Research. 22: 415-23. PMID 22968217 DOI: 10.1097/CMR.0b013e328358d98c |
0.042 |
|
| 2022 |
Thielmann CM, Matull J, Zaremba A, Murali R, Chorti E, Lodde G, Jansen P, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, et al. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. European Journal of Cancer (Oxford, England : 1990). 161: 99-107. PMID 34936949 DOI: 10.1016/j.ejca.2021.11.009 |
0.042 |
|
| 2017 |
D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH, Mohr P, Marquez-Rodas I, Charles J, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 226-235. PMID 28056206 DOI: 10.1200/Jco.2016.67.9258 |
0.041 |
|
| 2009 |
Diez C, Mohr P, Kuss O, Osten B, Silber RE, Hofmann HS. Impact of preoperative renal dysfunction on in-hospital mortality after solitary valve and combined valve and coronary procedures. The Annals of Thoracic Surgery. 87: 731-6. PMID 19231381 DOI: 10.1016/j.athoracsur.2008.11.055 |
0.041 |
|
| 2023 |
Haist M, Stege H, Rogall F, Tan Y, von Wasielewski I, Klespe KC, Meier F, Mohr P, Kähler KC, Weichenthal M, Hauschild A, Schadendorf D, Ugurel S, Lodde G, Zimmer L, et al. Treatment management for -mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG. Journal For Immunotherapy of Cancer. 11. PMID 37730278 DOI: 10.1136/jitc-2023-007630 |
0.039 |
|
| 2003 |
Kowalzick L, Rogozinski T, Wimheuer R, Pilz J, Manske U, Scholz A, Fierlbeck G, Mohr P, Ochsendorf F, Wagner G, Gaus W, Brzoska J, Jablonska S. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study. European Journal of Dermatology : Ejd. 12: 558-61. PMID 12459527 |
0.039 |
|
| 2022 |
Ebner C, Mori S, Mohr P, Peng Y, Schmalstieg D, Wetzstein G, Kalkofen D. Video See-Through Mixed Reality with Focus Cues. Ieee Transactions On Visualization and Computer Graphics. PMID 35167471 DOI: 10.1109/TVCG.2022.3150504 |
0.037 |
|
| 2004 |
Booker-Milburn KI, Jenkins H, Charmant JP, Mohr P. Synthesis of the reported structure of pogostol and a total aynthesis of (+/-)-kessane without the use of protecting groups. Organic Letters. 5: 3309-12. PMID 12943414 DOI: 10.1021/ol035373u |
0.036 |
|
| 2013 |
Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, ... ... Mohr P, et al. S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 11: 563-602. PMID 23721604 DOI: 10.1111/Ddg.12044 |
0.033 |
|
| 1998 |
Barbier P, Mohr P, Muller M, Masciadri R. Efficient Fluorination with Tetrabutylammonium Dihydrogen Trifluoride in a Novel Approach toward 1-alpha-Fluoro-25-hydroxy-vitamin D(3) Analogues. The Journal of Organic Chemistry. 63: 6984-6989. PMID 11672321 |
0.033 |
|
| 2016 |
Huebner J, Mohr P, Simon JC, Fluck M, Berking C, Zimmer L, Loquai C. Gebrauch von Komplementärmedizin bei Patienten mit metastasierendem Melanom unter Therapie mit Ipilimumab innerhalb einer klinischen Studie. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 14: 508-13. PMID 27119473 DOI: 10.1111/ddg.12750_g |
0.03 |
|
| 2010 |
Kuhn B, Mohr P, Stahl M. Intramolecular hydrogen bonding in medicinal chemistry. Journal of Medicinal Chemistry. 53: 2601-11. PMID 20175530 DOI: 10.1021/jm100087s |
0.029 |
|
| 2012 |
Pliquett RU, Mohr P, El Din Mukhtar B, Girndt M, Markau S. Plasmapheresis leading to remission of refractory nephrotic syndrome due to fibrillary glomerulonephritis: a case report. Journal of Medical Case Reports. 6: 116. PMID 22531147 DOI: 10.1186/1752-1947-6-116 |
0.029 |
|
| 2009 |
Hauschild A, Popp G, Stockfleth E, Meyer KG, Imberger D, Mohr P, Itschert G, Kaufmann R, Neuber K, Frambach Y, Gollnick H, Brunnert M, Stocker M, Ortland C, Karrer S. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. Experimental Dermatology. 18: 116-21. PMID 18643849 DOI: 10.1111/j.1600-0625.2008.00770.x |
0.029 |
|
| 2017 |
Ebner F, de Gregorio N, Rempen A, Mohr P, de Gregorio A, Wöckel A, Janni W, Witucki G. To clip or not to clip the breast tumor bed? A retrospective look at the geographic miss index and normal tissue index of 110 patients with breast cancer. Journal of the Turkish German Gynecological Association. 18: 67-71. PMID 28400348 DOI: 10.4274/jtgga.2016.0222 |
0.028 |
|
| 2019 |
Mohr P, Haferkamp S, Pinter A, Weishaupt C, Huber MA, Downey G, Öhrling K, Loquai C, Louie KS. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey. Advances in Therapy. 36: 101-117. PMID 30536143 DOI: 10.1007/s12325-018-0850-6 |
0.028 |
|
| 2018 |
Wouters MW, Michielin O, Bastiaannet E, Beishon M, Catalano O, Del Marmol V, Delgado-Bolton R, Dendale R, Trill MD, Ferrari A, Forsea AM, Kreckel H, Lövey J, Luyten G, Massi D, ... Mohr P, et al. ECCO essential requirements for quality cancer care: Melanoma. Critical Reviews in Oncology/Hematology. 122: 164-178. PMID 29458785 DOI: 10.1016/J.Critrevonc.2017.12.020 |
0.028 |
|
| 2020 |
Steeb T, Wessely A, Alter M, Bayerl C, Bender A, Bruning G, Dabrowski E, Debus D, Devereux N, Dippel E, Drexler K, Dücker P, Dummer R, Emmert S, Elsner P, ... ... Mohr P, et al. Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). Journal of Cancer Research and Clinical Oncology. PMID 33219855 DOI: 10.1007/s00432-020-03450-0 |
0.027 |
|
| 2015 |
Hauschild A, Mohr P. Rational, visions and limits of immuno-oncology: Checkpoint inhibition as a new therapeutic principle of cancer therapy Oncology Research and Treatment. 38: 2-5. PMID 25966811 |
0.025 |
|
| 2023 |
Leiter U, Heppt MV, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, ... ... Mohr P, et al. S3-Leitlinie "Aktinische Keratose und Plattenepithelkarzinom der Haut" - Update 2023, Teil 2: Epidemiologie und Ätiologie, Diagnostik, Therapie des invasiven Plattenepithelkarzinoms der Haut, Nachsorge und Prävention: S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 21: 1422-1434. PMID 37946644 DOI: 10.1111/ddg.15256_g |
0.022 |
|
| 2019 |
Ugurel S, Kortmann RD, Mohr P, Mentzel T, Garbe C, Breuninger H, Bauer S, Grabbe S. S1-Leitlinie Dermatofibrosarcoma protuberans (DFSP) - Update 2018. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 17: 663-668. PMID 31241846 DOI: 10.1111/ddg.13849_g |
0.022 |
|
| 2017 |
McArthur GA, Mohr P, Ascierto PA, Arance A, Banos Hernaez A, Kaskel P, Weichenthal M, Shinde R, Stevinson K. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). The Oncologist. 22: 951-962. PMID 28526721 DOI: 10.1634/theoncologist.2016-0272 |
0.021 |
|
| 2021 |
Garbe C, Schadendorf D, Tilgen W, Gutzmer R, Berking C, Mohr P, Kaufmann R, Breitbart E, Weber C, Volkenandt M, Hauschild A. 30 years German Dermatologic Cooperative Oncology Group (DeCOG). Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 19: 1682-1697. PMID 34677891 DOI: 10.1111/ddg.14628 |
0.019 |
|
| 2013 |
Ugurel S, Kortmann RD, Mohr P, Mentzel T, Garbe C, Breuninger H. Brief S2k guidelines - Dermatofibrosarcoma protuberans Jddg - Journal of the German Society of Dermatology. 11: 16-18. PMID 23734891 DOI: 10.1111/j.1610-0379.2012.00.x |
0.019 |
|
| 2008 |
Cristalli G, Mátyus P, Mohr P, Ronsisvalle G, de Souza NJ, Tsantili-Kakoulidou A. European medicinal chemistry education: the transformational accomplishments and challenges. Chemmedchem. 3: 561-3. PMID 18181123 DOI: 10.1002/Cmdc.200700316 |
0.018 |
|
| 2009 |
Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-Sánchez R, Alker A, Polonchuk L, Christ AD. Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorganic & Medicinal Chemistry Letters. 19: 6106-13. PMID 19786348 DOI: 10.1016/j.bmcl.2009.09.024 |
0.018 |
|
| 2010 |
Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P. Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorganic & Medicinal Chemistry Letters. 20: 4521-5. PMID 20580234 DOI: 10.1016/j.bmcl.2010.06.026 |
0.018 |
|
| 2010 |
Dutzler R, Ernstb B, Hediger MA, Keppler D, Mohr P, Neidhart W, Märki HP. Channels and transporters. Mini-symposium of the Division of Medicinal Chemistry (DMC) of the Swiss Chemical Society (SCS) at the Department of Chemistry, University of Basel, May 27, 2010. Chimia. 64: 662-6. PMID 21138110 |
0.018 |
|
| 2013 |
Fry D, Huang KS, Di Lello P, Mohr P, Müller K, So SS, Harada T, Stahl M, Vu B, Mauser H. Design of libraries targeting protein-protein interfaces. Chemmedchem. 8: 726-32. PMID 23436619 DOI: 10.1002/cmdc.201200540 |
0.018 |
|
| 2009 |
Ugurel S, Kortmann RD, Mohr P, Mentzel T, Garbe C, Breuninger H. Short German guidelines: dermatofibrosarcoma protuberans. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. S17-8. PMID 18801137 DOI: 10.1111/j.1610-0387.2008.06709.x |
0.016 |
|
| 2007 |
Mohr P, Brieger S, Stahl J, Witucki G. Linearity of the dose monitor system at low monitor units. Strahlentherapie Und Onkologie : Organ Der Deutschen Rã¶Ntgengesellschaft ... [Et Al]. 183: 327-31. PMID 17520187 DOI: 10.1007/s00066-007-1596-2 |
0.016 |
|
| 2019 |
Krensel M, Petersen J, Mohr P, Weishaupt C, Augustin J, Schäfer I. Estimating prevalence and incidence of skin cancer in Germany. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 17: 1239-1249. PMID 31885171 DOI: 10.1111/ddg.14002 |
0.015 |
|
| 2007 |
Mohr P. [Adjuvant interferon therapy in malignant melanoma]. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 5: 543-5. PMID 17537052 DOI: 10.1111/j.1610-0387.2007.07576.x |
0.015 |
|
| 2010 |
Grether U, Klaus W, Kuhn B, Maerki HP, Mohr P, Wright MB. New Insights on the mechanism of PPAR-targeted drugs. Chemmedchem. 5: 1973-6. PMID 21069658 DOI: 10.1002/cmdc.201000446 |
0.013 |
|
| 2023 |
Heppt MV, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, ... ... Mohr P, et al. S3-Leitlinie "Aktinische Keratose und Plattenepithelkarzinom der Haut" - Update 2023, Teil 1: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen: S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 21: 1249-1262. PMID 37845050 DOI: 10.1111/ddg.15231_g |
0.012 |
|
| 2021 |
Garbe C, Schadendorf D, Tilgen W, Gutzmer R, Berking C, Mohr P, Kaufmann R, Breitbart E, Weber C, Volkenandt M, Hauschild A. 30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO). Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 19: 1682-1697. PMID 34677896 DOI: 10.1111/ddg.14628_g |
0.011 |
|
| 2023 |
Heppt MV, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, ... ... Mohr P, et al. S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 21: 1249-1262. PMID 37845077 DOI: 10.1111/ddg.15231 |
0.01 |
|
| 2020 |
van Akkooi ACJ, Haferkamp S, Papa S, Franke V, Pinter A, Weishaupt C, Huber MA, Loquai C, Richtig E, Gokani P, Öhrling K, Louie KS, Mohr P. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries. Advances in Therapy. PMID 33368016 DOI: 10.1007/s12325-020-01590-w |
0.01 |
|
| 2020 |
Hauschild A, Mohr P. Interdisziplinäres Experten-Treffen „Quo vadis beim kutanen Plattenepithelkarzinom“. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 18: 1207-1208. PMID 33112073 DOI: 10.1111/ddg.14287_g |
0.01 |
|
| 2020 |
Ugurel S, Mohr P. Adjuvante Therapie des Melanoms und translationale Registerstudie TRIM-ADJUVANT. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 18: 659. PMID 32519496 DOI: 10.1111/ddg.14106_g |
0.01 |
|
| 2016 |
Wilden SM, Lang BM, Mohr P, Grabbe S. Checkpoint-Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 14: 685-97. PMID 27373243 DOI: 10.1111/ddg.13012_g |
0.01 |
|
| 2016 |
Mohr P, Starostzik C. Deep freezing, curettage or rather cream application Mmw Fortschritte Der Medizin. 158: 18. PMID 27071564 DOI: 10.1007/s15006-016-8035-1 |
0.01 |
|
| 2014 |
Greinert R, Breitbart EW, Mohr P, Volkmer B. Health initiatives for the prevention of skin cancer Advances in Experimental Medicine and Biology. 810: 485-499. PMID 25207383 |
0.01 |
|
| 2010 |
Sprecher U, Mohr P, Martin RE, Maerki HP, Sanchez RA, Binggeli A, Künnecke B, Christ AD. Novel, non-peptidic somatostatin receptor subtype 5 antagonists improve glucose tolerance in rodents. Regulatory Peptides. 159: 19-27. PMID 19761802 DOI: 10.1016/j.regpep.2009.09.006 |
0.01 |
|
| Hide low-probability matches. |